A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BRIDGE
- Sponsors Oncopeptides
- 26 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.
- 26 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Feb 2020.
- 24 Apr 2019 This trial was discussed at the webcast 2019. Updated data will be presented at ASH in H2 2019, as reported in a webcast 2019.